Received: 6 July 2020
Accepted: 24 August 2020
First Online: 1 September 2020
Ethics approval and consent to participate
: This study was an observational, retrospective study that did not jeopardize patient’s clinical management and/or identity. Therefore, ethical committee approval and signature of informed consent to participate were both waived by the ethics committee of Instituto Nacional de Cancerologia.
: All authors approved the final version of this manuscript
: Dr. OA reports personal fees from Pfizer, grants and personal fees from Astra Zeneca, grants and personal fees from Boehringer Ingelheim, personal fees from Lilly, personal fees from Merck, personal fees from Bristol Myers Squibb, grants and personal fees from Roche; all of them outside the submitted work; Dr. Herman Soto reports personal fees and grants from AZ, Boehringer, Roche, Bayer, Takeda, Pfizer and Novartis, all of them outside the submited work. All the remaining authors declare no conflict of interest.